As far as the community-dwelling prescriptions are concerned, the most frequent pair was ACE-inhibitors—NSAIDs (7.2%), followed by calcium channel blockers—α-blockers (2.4%; including both antihypertensive and drugs used in benign prostatic hypertrophy) and by antidiabetics—beta-blockers (2.3%). Here, ACE is linked to benign prostatic hyperplasia.